When did ImmunityBio, Inc. report Q4 2024 earnings?

ImmunityBio, Inc. (IBRX) reported Q4 2024 earnings on March 3, 2025 before market open.

What were ImmunityBio, Inc.'s Q4 2024 revenue and EPS?

ImmunityBio, Inc. reported revenue of $7.6M and eps of $-0.15 for Q4 2024.

Did ImmunityBio, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $9.6M by $2.1M. EPS beat the consensus estimate of $-0.26 by $0.11.

Where can I find ImmunityBio, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001326110-25-000033) directly on SEC EDGAR. The filing index links above go to sec.gov.

ImmunityBio, Inc. IBRX Q4 2024 Annual earnings

Reported March 3, 2025 · Before market open

Revenue$7.6MMiss by $2.1M

EPS-$0.15Beat by $0.11

Revenue estimate$9.6M

EPS estimate-$0.26

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$49.7M

EPS estimate-$0.09

Financials

Q4 2024

Income statement

See full

Revenue$7.6M+5,333%

Gross profit$7.6M+5,333%

Operating income-$69.4M+18.7%

Net income-$59.2M+74.7%

EPS (diluted)-$0.09+76.3%

Balance sheet

See full

Cash & equivalents$143.4M-46.0%

Total debt$326.7M+62.8%

Total equity-$489.1M+16.7%

Total assets$382.9M-24.1%

Cash flow

See full

Operating cash flow-$85.1M+26.1%

CapEx$2.1M-73.5%

Free cash flow-$87.3M+29.2%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.87B-44.5%

Enterprise value$2.05B-37.9%

P/S126.8×-5,288×

Profitability

See full

Gross margin100%0.0pp

Operating margin-2,334.2%-1,143pp

Net margin-2,804.8%-1,381pp

FCF margin-2,700.1%-1,321pp

Returns & leverage

See full

Current ratio3.4×-1.7×

Segments

By segment

See full

Reportable Segment$7.6M+4,757%

By geography

See full

U.S.$7.2M+93,023%

Versus estimates

Revenue

Q1 2026$44.2MBeat by $1.1M Q4 2025$38.3MMiss by $76.0K Q3 2025$32.1MMiss by $5.7M Q2 2025$26.4MMiss by $5.5M Q1 2025$16.5MMiss by $83.0K

Q4 2024$7.6MMiss by $2.1M

Diluted EPS

Q1 2026-$0.09Miss by $0.01 Q4 2025-$0.06Beat by $0.02 Q3 2025-$0.07Beat by $0.03 Q2 2025-$0.10In line Q1 2025-$0.15Miss by $0.03

Q4 2024-$0.15Beat by $0.11

Ask the moment ImmunityBio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ImmunityBio, Inc. report Q4 2024 earnings?: ImmunityBio, Inc. (IBRX) reported Q4 2024 earnings on March 3, 2025 before market open.
What were ImmunityBio, Inc.'s Q4 2024 revenue and EPS?: ImmunityBio, Inc. reported revenue of $7.6M and eps of $-0.15 for Q4 2024.
Did ImmunityBio, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $9.6M by $2.1M. EPS beat the consensus estimate of $-0.26 by $0.11.
Where can I find ImmunityBio, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001326110-25-000033) directly on SEC EDGAR. The filing index links above go to sec.gov.